Loading
Life sciences · Review
Journal of the European Academy of Dermatology and Venereology · November 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Review.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Obesity is characterized by chronic low-grade inflammation and metabolic dysfunction. It is a major risk factor for hidradenitis suppurativa (HS), where it is associated with increased disease severity and metabolic comorbidity. Obesity promotes a pro-inflammatory, immunometabolic state marked by adipokine imbalance and alters the local skin environment through mechanical stress, occlusion and microbiome disruption. Mechanistic transcriptomic analyses further suggest that obesity induces tissue-specific changes in HS skin, including metabolic signalling in lesions and early barrier dysfunction in perilesional skin. In practice, obesity is associated with more severe and treatment-refractory disease but remains a modifiable risk factor. Weight loss, bariatric surgery and metabolism-directed therapies show potential to reduce disease burden, although controlled studies are limited. Overall, obesity acts as both a systemic and local modifier of HS, supporting its classification as an immunometabolic disorder.